Fermenta Biotech Q1 FY27 results: revenue falls, PAT down YoY

Revenue DeclineExceptional ItemResults View source PDF Explain this filing

FERMENTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-12.8%Reaction day

₹547.40

prior close

₹524.55

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-12.6% vs market

Pharmaceuticals peers, median of 164sector+0.1%-12.9% vs sector

On the reaction day the stock moved 12.6 pts less than Nifty Microcap 250 and 12.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-12.1

10m

-14.9

15m

-13.8

30m

-14.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-12.8-0.2-12.6+0.1-12.9

Next day

-13.3+0.2-13.5-0.4-12.8

-16.1+0.4-16.5+0.1-16.3

-17.8+0.4-18.2-0.4-17.4

-16.1+0.6-16.7-0.9-15.3

-16.5+0.9-17.4-0.5-16.0

-15.2+0.9-16.1-1.0-14.2

15d

-10.8+0.9-11.7-0.6-10.2

-13.2+2.3-15.6+1.1-14.4

-4.7-1.1-3.6-3.1-1.6

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 results (June 30, 2026) with unmodified auditor opinion. Standalone revenue at Rs 11,183.93 lakhs, down 6 percent YoY from Rs 11,901.87 lakhs. Standalone PAT at Rs 1,498.58 lakhs versus Rs 1,623.38 lakhs YoY. Consolidated PAT dropped sharply to Rs 953.15 lakhs from Rs 2,160.17 lakhs YoY, hurt by subsidiary losses of Rs 398.17 lakhs. An exceptional item of Rs 907.14 lakhs (provision reversal on recovered receivables) boosted prior quarter. Company granted 3,95,400 ESOPs at Rs 83.67 per option.

Likely market impact

Revenue and profit decline YoY; subsidiary drag weighs on consolidated earnings. Clean audit opinion but weak show.